Navigation Links
AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
Date:4/30/2008

eek 52, 54, 78 and 80 will be followed up to Week 90.

A second, similarly designed multi-center Phase 3 efficacy study, being led by Prof. Frans M.J. Debruyne, M.D., Ph.D., from The Netherlands, will enroll approximately 400 patients in Europe. The third Phase 3 trial scheduled to start shortly, is an open-label, single-armed multi-center safety study involving approximately 500 patients in both North America and Europe, and is being led by Joel Kaufman, M.D., Associate Clinical Professor of Urology, University of Colorado School of Medicine, Denver, Colorado, and Urology Research Options, Aurora, Colorado.

The primary endpoint for both North American and European efficacy studies is the change in I-PSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH-symptom progression and the need for BPH-related surgery. Safety endpoints include changes in sexual function. Other important endpoints include plasma changes in levels of testosterone, and assessment of other adverse events.

The cetrorelix Phase 3 program is based on comprehensive clinical practice guidelines to ensure quality control, including input from expert advisors on study design, publishing results in peer-reviewed journals and discussion of the studies with regulatory agencies.

Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men - affecting more than 20 million men in the United States - but its etiology is far from being completely understood. Data from ongoing research suggest BPH and its associated lower urinary tract symptoms (LUTS) are more complex conditions than once thought. While previous research on BPH etiology tended to focus on testosterone and other hormones, more recent research suggests other factors may play a greater role in the development of BPH and LUTS - including inflammation, various growth factors, and adrenoreceptors.

BPH-associated LUTS inc
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Announces Changes to its Management Team
4. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
5. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
6. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
7. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
10. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
11. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 02, 2015 , ... Spirax Sarco , ... to its eCommerce site Spirax Sarco Anytime. This platform, offering unique online ordering ... place your next order? Log on to Spirax Sarco Anytime and within minutes ...
(Date:9/1/2015)... , Sept. 1, 2015 Prostate ... death in American men. One in seven ... 233,000 new cases are diagnosed annually. That said, ... using a powerful new technique, MRI Fusion Biopsy, ... large cancer lesions, treating only the affected areas ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... recombinant antibodies, announced today that the National Institutes of Health (NIH) has awarded ... will be administered by the NIH’s National Institute of Diabetes and Digestive and ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... the neuro and pain management space join prominent academics and key investors for ... at Harvard Medical School in Boston. , Neuro Advance Boston focuses on ...
Breaking Biology Technology:Spirax Sarco Announces New Features to Anytime Platform 2September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2
... (Nasdaq: NYER ) reported results for the fiscal year ... 30, 2008 increased $6.6,million or 10.2% to $71.2 million from ... for the fiscal year ended June 30, 2008 was,$403,520 or ... $86,446 or $.02,per share for the previous fiscal year., ...
... MirixaPro(SM) chosen to enable patient care services in Australia through ... ... NCPA 110th Annual Convention --,Mirixa Corporation, the leader in pharmacy-based ... of Australia, announced,today that they have signed a definitive technology ...
... (OTC,Pink Sheets: SNDY) is pleased to announce that the ... on the Pinksheets Electronic OTC Markets from,Limited Information to ... their Issuer Information Statement, which will be accompanied,by an ... status,upgraded by the end of the quarter., A ...
Cached Biology Technology:Nyer Medical Group, Inc. Reports Revenues of $71.2 Million With Net Loss of $.10 Per Share for Fiscal Year 2008 2Nyer Medical Group, Inc. Reports Revenues of $71.2 Million With Net Loss of $.10 Per Share for Fiscal Year 2008 3Mirixa Announces Agreement With the Pharmacy Guild of Australia 2Mirixa Announces Agreement With the Pharmacy Guild of Australia 3Solos Endoscopy, Inc. in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information 2
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... cancer,patients have an abnormality in a specific cell ... pathway may be,especially effective for treating the disease, ... D. Anderson Cancer Center.", , A clearer picture ... 3 kinase (PI3K),pathway to breast cancer development, says ...
... got updated to version 5.0. Proteins are classified,by ... known,pathways. Its main use is probably microarray analysis ... output. Best of,all, its available freely . ... freely in the Nucleic acids research Journal . ...
... An estrogen-like chemical,commonly used to synthesize plastic food ... a specific category of prostate cancer cell,potentially affecting ... to a study published in the January 1 ... to be vulnerable to,exposure to the chemical BPA ...
Cached Biology News:PANTHER Protein Classification System Database 5.0 2PANTHER Protein Classification System Database 5.0 3Estrogen-like Component of Plastic Stimulates Growth of Certain Prostate Cancer Cells 2
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
ANTI S. ENTERID LPS...
... This DuoSet ELISA Development kit contains the ... sandwich ELISAs to measure natural and recombinant ... serum. Each kit contains sufficient materials to ... provided that the following conditions are met: ...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant rat ... Each kit contains sufficient materials to ... provided that the following conditions are met: ...
Biology Products: